Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Pre-treatment ZNF683⁺ effector CD8⁺ T cells predict response to BiTE therapy in acute lymphoblastic leukemia: Insights from single-cell and TCR sequencing

Linghui Zhou, Cheng Zu, Kexin Wang, Mingming Zhang, Shan Fu, Jingjing Feng, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 5086.

https://doi.org/10.1182/blood-2025-5086

Published: 2025

Journal Articles

Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis

Blood (2025) 146 (Supplement 1): 2395.

https://doi.org/10.1182/blood-2025-2395

Published: 2025

Journal Articles

OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study

Yongxian Hu, Mingming Zhang, Yajing Zhang, Shan Fu, Jingjing Feng, Guoai Su, Dan Song, Chia-Wei Chang, Hongmei Wang, Sihui Guan, He Huang

Blood (2025) 146 (Supplement 1): 2387.

https://doi.org/10.1182/blood-2025-2387

Published: 2025

Journal Articles

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies

Tingting Yang, Mingming Zhang, Mengqi Yu, Shan Fu, Jingjing Feng, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Zhang, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2025-1040

Published: 2025

Journal Articles

Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma

Mingming Zhang, Lianxuan Liu, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Zhang, He Huang

Blood (2025) 146 (Supplement 1): 1940.

https://doi.org/10.1182/blood-2025-1940

Published: 2025

Journal Articles

Baseline PET-CT in predicting CRS and survival outcomes of R/R MM patients following CAR T-cell therapy

Pingnan Xiao, Xin Zhao, Linqin Wang, Yixue Li, Mingming Zhang, Jingjing Feng, Shan Fu, Houli Zhao, Kui zhao, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 5855.

https://doi.org/10.1182/blood-2025-5855

Published: 2025

Journal Articles

Donor-derived secondary CAR-T cell therapy for relapsed leukemia following initial CAR-T bridged to allogeneic transplantation: Efficacy and safety analysis

Yiqing Ren, Weiming Zhang, Guoqing Wei, Mingming Zhang, Shan Fu, Jingjing Feng, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 5941.

https://doi.org/10.1182/blood-2025-5941

Published: 2025

Journal Articles

CD7-negative T cell immune reconstitution after CD7-targted CAR-T cell therapy

Haiqiong Zheng, Houli Zhao, Xin Jin, Delin Kong, Ruirui Jing, Jiazhen Cui, Simao Huang, Mingming Zhang, Jingjing Feng, Shan Fu, Guoqing Wei, Alex H Chang, Dongrui Wang, Yongxian Hu, He Huang

Blood (2025) 146 (Supplement 1): 5900.

https://doi.org/10.1182/blood-2025-5900

Published: 2025

Journal Articles

One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus

Jingjing Feng, Heng Cao, Mingming Zhang, Xintong Feng, Shan Fu, Guoqing Wei, Ruimin Hong, Lianjun Shen, Jin Lin, Zhihong Liu, Jia Liu, Yongxian Hu, He Huang

Blood (2025) 146 (Supplement 1): 2384.

https://doi.org/10.1182/blood-2025-2384

Published: 2025

Journal Articles

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2024-209418

Published: 2024

Journal Articles

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Tingting Yang, Yetian Dong, Mingming Zhang, Jingjing Feng, Shan Fu, Pingnan Xiao, Ruimin Hong, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 2818.

https://doi.org/10.1182/blood-2024-210124

Published: 2024

Journal Articles

TRA/D Rearrangements As a New Potential Alternative Prognostic Biomarker in Pediatric B-Cell Acute Lymphoblastic Leukemia

Jiajia Zheng, Xinni Bian, Jun Lu, Peifang Xiao, Hailong He, Yi Wang, Jie Li, Junjie Fan, Yanhua Yao, Jing Ling, Yiting Wang, Nan Chen, Xingping Lang, Jingjing Feng, Xiaojun Chen, Huafei Chen, Sheng Xiao, Sheng Xiao, Shaoyan Hu

Blood (2024) 144 (Supplement 1): 5931.

https://doi.org/10.1182/blood-2024-212299

Published: 2024

Journal Articles

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2024) 144 (Supplement 1): 91.

https://doi.org/10.1182/blood-2024-210462

Published: 2024

Journal Articles

Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

Blood (2023) 142 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2023-185697

Published: 2023

Journal Articles

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2023) 142 (Supplement 1): 891.

https://doi.org/10.1182/blood-2023-186225

Published: 2023

Journal Articles

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL

Yongxian HU, Guoqing Wei, Shan Fu, Pingnan Xiao, Jingjing Feng, Mingming Zhang, Xingbing Wang, Dongrui Wang, Jun Li, He Huang

Blood (2023) 142 (Supplement 1): 2111.

https://doi.org/10.1182/blood-2023-189052

Published: 2023

Journal Articles

CD19/BCMA CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus - Safety and Preliminary Efficacy Data from a Phase I Clinical Study

Jingjing Feng, Yongxian HU, Alex H. Chang, He Huang

Blood (2023) 142 (Supplement 1): 4835.

https://doi.org/10.1182/blood-2023-186669

Published: 2023

Journal Articles

A Multicenter Study of CAR-T Cell Therapy for Relapse of B-ALL Post Allogeneic Stem Cell Transplantation

Jingjing Feng, He Huang, Yongxian HU

Blood (2023) 142 (Supplement 1): 3485.

https://doi.org/10.1182/blood-2023-184740

Published: 2023

Journal Articles

Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation

Xiangjun Zeng, Xiaoqing Li, Xia Li, Cong Wei, Ce Shi, Kejia Hu, Delin Kong, Qian Luo, Yulin Xu, Wei Shan, Meng Zhang, Jimin Shi, Jingjing Feng, Yingli Han, He Huang, Pengxu Qian

Blood (2023) 141 (14): 1691–1707.

https://doi.org/10.1182/blood.2022017514

Published: 2023

Includes: Supplemental data

Journal Articles

Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial

Jingjing Feng, Yongxian Hu, Mingming Zhang, Heng Cao, Yini Ke, Huijun Xu, Jiazhen Cui, Yanlei Zhang, Alex Hongsheng Chang, Jin Lin, Guoqing Wei, He Huang

Blood (2022) 140 (Supplement 1): 10335–10336.

https://doi.org/10.1182/blood-2022-169265

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pre-treatment ZNF683⁺ effector CD8⁺ T cells predict response to BiTE therapy in acute lymphoblastic leukemia: Insights from single-cell and TCR sequencing

Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis

OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies

Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma

Baseline PET-CT in predicting CRS and survival outcomes of R/R MM patients following CAR T-cell therapy

Donor-derived secondary CAR-T cell therapy for relapsed leukemia following initial CAR-T bridged to allogeneic transplantation: Efficacy and safety analysis

CD7-negative T cell immune reconstitution after CD7-targted CAR-T cell therapy

One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

TRA/D Rearrangements As a New Potential Alternative Prognostic Biomarker in Pediatric B-Cell Acute Lymphoblastic Leukemia

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL

CD19/BCMA CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus - Safety and Preliminary Efficacy Data from a Phase I Clinical Study

A Multicenter Study of CAR-T Cell Therapy for Relapse of B-ALL Post Allogeneic Stem Cell Transplantation

Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation

Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only